AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3775255 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, buffered solution, doses of 10-60 mg
Number of subjects: 0
Study 3775255 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, buffered solution
Number of subjects: 0
Study 31552510 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise training (CET) - resistance and aerobic training three times a week for 16 weeks
Number of subjects: 23
Study 31552510 — intervention group
Group type: COMPARATOR
Intervention: Control group - recreational activities twice a week for 16 weeks
Number of subjects: 23
Study 30554821 — intervention group
Group type: EXPERIMENTAL
Intervention: E2: APA for 2 seconds/mm2-ethanol cleaned
Number of subjects: 150
Study 30554821 — intervention group
Group type: EXPERIMENTAL
Intervention: E5: APA for 5 seconds/mm2-ethanol cleaned
Number of subjects: 150
Study 30554821 — intervention group
Group type: COMPARATOR
Intervention: Control: NT (no treatment)
Number of subjects: 150
Study 30554821 — intervention group
Group type: EXPERIMENTAL
Intervention: E10: APA for 10 seconds/mm2-ethanol cleaned
Number of subjects: 150
Study 28606970 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight Control (TC; 4 weekly review with therapy escalation if criteria not met)
Number of subjects: 206
Study 28606970 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC; 12 weekly review)
Number of subjects: 206
Study 28606970 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight Control (TC) for participants with oligoarthritis
Number of subjects: 206
Study 28606970 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC) for participants with oligoarthritis
Number of subjects: 206
Study 26804926 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice (PJ)
Number of subjects: 38
Study 25051297 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure treatment at 08.00 a.m. (high cortisol group)
Number of subjects: 60
Study 25051297 — intervention group
Group type: COMPARATOR
Intervention: Exposure treatment at 06.00 p.m. (low cortisol group)
Number of subjects: 60
Study 22990062 — intervention group
Group type: COMPARATOR
Intervention: Monopolar transurethral resection of the prostate
Number of subjects: 136
Study 22990062 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar transurethral resection of the prostate
Number of subjects: 136
Study 18667099 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT) plus treatment as usual (TAU)
Number of subjects: 52
Study 18667099 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 52
Study 17315156 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine
Number of subjects: 491
Study 17315156 — intervention group
Group type: COMPARATOR
Intervention: Intensive chemotherapy (Group A)
Number of subjects: 491
Study 17315156 — intervention group
Group type: COMPARATOR
Intervention: Intensive chemotherapy (Group B)
Number of subjects: 491
Study 15357159 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate dressing
Number of subjects: 0
Study 11593871 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-MCT/LCT 1% (Propofol-Lipuro)
Number of subjects: 40
Study 11593871 — intervention group
Group type: COMPARATOR
Intervention: Propofol-LCT 1% (Disoprivan)
Number of subjects: 40
Study 9673472 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% betaxolol HCI, twice-daily bilateral topical ocular dosing for one year
Number of subjects: 18
Study 9673472 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% betaxolol HCI
Number of subjects: 18
Study 8045971 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 10
Study 8045971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2454788 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulants (vanillin, phenylethyl alcohol, limonene, menthol, anethol, benzaldehyde, carbon dioxide, mixture of vanillin and carbon dioxide)
Number of subjects: 13
Study 2454788 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of carbon dioxide and vanillin
Number of subjects: 13
Study 2454788 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemosensory evoked potentials to substances perceived by anosmics (vanillin, phenylethyl alcohol)
Number of subjects: 13
Study 2454788 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemosensory evoked potentials to CO2
Number of subjects: 13
Study 30277507 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored implementation programme delivered by practice nurses
Number of subjects: 2184
Study 30277507 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 2184
Study 27255289 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 25 mg/m2 twice daily (cohort 3)
Number of subjects: 18
Study 27255289 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 20 mg/m2 twice daily (cohort 2)
Number of subjects: 18
Study 26095389 — intervention group
Group type: EXPERIMENTAL
Intervention: Oesophagectomy (92-OP)
Number of subjects: 540
Study 26095389 — intervention group
Group type: EXPERIMENTAL
Intervention: Oesophagectomy plus postoperative chemotherapy (92-POST)
Number of subjects: 540
Study 26095389 — intervention group
Group type: COMPARATOR
Intervention: Postoperative chemotherapy (99-POST)
Number of subjects: 540
Study 26095389 — intervention group
Group type: COMPARATOR
Intervention: Preoperative chemotherapy (99-PRE)
Number of subjects: 540
Study 23258223 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix 240/80 mg
Number of subjects: 40
Study 23258223 — intervention group
Group type: COMPARATOR
Intervention: Goserelin 3.6 mg + bicalutamide flare protection (G+B)
Number of subjects: 40
Study 21329822 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine (CHX)
Number of subjects: 0
Study 21329822 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% cetrimide (CTR)
Number of subjects: 0
Study 21329822 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% sodium hypochlorite (NaOCl)
Number of subjects: 0
Study 21329822 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl and 0.2% CTR
Number of subjects: 0
Study 21329822 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% maleic acid (MA)
Number of subjects: 0
Study 21329822 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% CHX
Number of subjects: 0
Study 21329822 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% ethylendiaminetetraacetic (EDTA)
Number of subjects: 0
Study 21329822 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% MA or 17% EDTA followed by 0.2% CTR or 2% CHX
Number of subjects: 0
Study 21329822 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% CTR solution alone
Number of subjects: 0
Study 21329822 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations with 2% CHX or 0.2% CTR as final irrigating solution
Number of subjects: 0
Study 19863477 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide 15 mg weekly
Number of subjects: 40
Study 19863477 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide 30 mg weekly
Number of subjects: 40
Study 19863477 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide 50 mg biweekly
Number of subjects: 40
Study 19863477 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide 100 mg monthly
Number of subjects: 40
Study 19863477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16105862 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Arg infusion (30 g at 0.5 g/min)
Number of subjects: 9
Study 16105862 — intervention group
Group type: COMPARATOR
Intervention: Control (saline alone)
Number of subjects: 9
Study 16105862 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Arg infusion
Number of subjects: 9
Study 14749239 — intervention group
Group type: EXPERIMENTAL
Intervention: High fruit and vegetable consumption (>= 3 servings/d)
Number of subjects: 56
Study 14749239 — intervention group
Group type: COMPARATOR
Intervention: Low fruit and vegetable consumption (< 3 servings/d)
Number of subjects: 56
Study 15590800 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (short-acting morphine tablets and indomethacin rectal suppositories)
Number of subjects: 139
Study 15590800 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B (long-acting morphine tablets for baseline pain, short-acting morphine tablets for breakthrough pain, and naproxen rectal suppositories)
Number of subjects: 139
Study 15590800 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior hypogastric nerve block (SHNB)
Number of subjects: 139
Study 10673303 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Fr Teflon Tannenbaum stent (TT)
Number of subjects: 134
Study 10673303 — intervention group
Group type: COMPARATOR
Intervention: 10 Fr polyethylene Cotton-Leung stent (CL)
Number of subjects: 134
Study 11539901 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 81
Study 11539901 — intervention group
Group type: COMPARATOR
Intervention: Group B
Number of subjects: 81
Study 1283188 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine 16 mg
Number of subjects: 0
Study 1283188 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg
Number of subjects: 0
Study 1283188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3941792 — intervention group
Group type: EXPERIMENTAL
Intervention: gamma‐vinyl GABA therapy, 2 g daily for 2 weeks
Number of subjects: 6
Study 3941792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 28544762 — intervention group
Group type: EXPERIMENTAL
Intervention: tooth/tongue gel, tongue cleaner, and mouthwash containing amine fluoride/stannous fluoride and zinc lactate
Number of subjects: 66
Study 28544762 — intervention group
Group type: COMPARATOR
Intervention: standard fluoride dentifrice
Number of subjects: 66
Study 27524385 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgically assisted rapid maxillary expansion (SARME) without pterygomaxillary disjunction (PTMD)
Number of subjects: 15
Study 27524385 — intervention group
Group type: COMPARATOR
Intervention: Surgically assisted rapid maxillary expansion (SARME) with pterygomaxillary disjunction (PTMD)
Number of subjects: 15
Study 24382603 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based HIV prevention
Number of subjects: 721
Study 24382603 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent-only HIV prevention
Number of subjects: 721
Study 24382603 — intervention group
Group type: COMPARATOR
Intervention: Adolescent-only health promotion
Number of subjects: 721
Study 22430344 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% isopropyl alcohol instilled once a week for 2 months
Number of subjects: 20
Study 22430344 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment for 2 months)
Number of subjects: 20
Study 22430344 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% isopropyl alcohol instilled once a week for 2 months (after crossover)
Number of subjects: 20
Study 22430344 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment for 2 months after crossover)
Number of subjects: 20
Study 22430344 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 during treatment vs nontreatment
Number of subjects: 20
Study 22430344 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 during treatment vs nontreatment
Number of subjects: 20
Study 20686751 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose of alcohol (0.65 g/kg) administered twice on separate days
Number of subjects: 32
Study 18792702 — intervention group
Group type: EXPERIMENTAL
Intervention: EBS Multi + Compolute (EC; 3M ESPE)
Number of subjects: 31
Study 18792702 — intervention group
Group type: COMPARATOR
Intervention: Syntac + Variolink II low (SV; Ivoclar Vivadent)
Number of subjects: 31
Study 18792702 — intervention group
Group type: EXPERIMENTAL
Intervention: Both luting systems (EC and SV)
Number of subjects: 31
Study 15689760 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear plugs
Number of subjects: 201
Study 15689760 — intervention group
Group type: COMPARATOR
Intervention: No ear plugs
Number of subjects: 201
Study 12535286 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% urea cream
Number of subjects: 53
Study 12535286 — intervention group
Group type: COMPARATOR
Intervention: Lipid-rich cream
Number of subjects: 53
Study 10333653 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile discrimination measured by error rates of either hand
Number of subjects: 0
Study 8946295 — intervention group
Group type: EXPERIMENTAL
Intervention: Transscleral Nd:YAG cyclophotocoagulation (TYC)
Number of subjects: 479
Study 8946295 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative hypotony
Number of subjects: 479
Study 8946295 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up duration > 6 months
Number of subjects: 479
Study 1896198 — intervention group
Group type: EXPERIMENTAL
Intervention: ATS injection, oral metronidazole, amoxycillin, diazepam suppositoria plus pyridoxin injection 100 mg on the first day followed by 25 mg orally on the next days
Number of subjects: 31
Study 1896198 — intervention group
Group type: COMPARATOR
Intervention: ATS injection, oral metronidazole, amoxycillin, diazepam suppositoria
Number of subjects: 31
Study 6750396 — intervention group
Group type: EXPERIMENTAL
Intervention: Protriptyline treatment for 2 weeks
Number of subjects: 5
Study 6750396 — intervention group
Group type: EXPERIMENTAL
Intervention: Protriptyline treatment for 6 months
Number of subjects: 5
Study 30685099 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-C (per 1 mg/dl increase)
Number of subjects: 9631
Study 30685099 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 9631
Study 28759606 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced education (Clinical Pearls)
Number of subjects: 0
Study 28759606 — intervention group
Group type: COMPARATOR
Intervention: Control (non-reinforced knowledge)
Number of subjects: 0
Study 25790846 — intervention group
Group type: COMPARATOR
Intervention: Conventional temperature control (group A)
Number of subjects: 15
Study 25790846 — intervention group
Group type: EXPERIMENTAL
Intervention: Impedance control (group B)
Number of subjects: 15
Study 23438224 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (1 mg·kg(‐1) BW)
Number of subjects: 24
Study 23438224 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg·kg(‐1) BW)
Number of subjects: 24
Study 23438224 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg·kg(‐1) BW)
Number of subjects: 24
Study 23438224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 21953854 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine hydrochloride 150 mg modified release capsules of Ranbaxy
Number of subjects: 0
Study 21953854 — intervention group
Group type: COMPARATOR
Intervention: EFEXOR®-XR 150 mg capsules of Wyeth
Number of subjects: 0
Study 19052813 — intervention group
Group type: EXPERIMENTAL
Intervention: Escin 5 mg
Number of subjects: 72
Study 19052813 — intervention group
Group type: EXPERIMENTAL
Intervention: Escin 15 mg
Number of subjects: 72
Study 19052813 — intervention group
Group type: EXPERIMENTAL
Intervention: Escin 25 mg
Number of subjects: 72
Study 17413838 — intervention group
Group type: EXPERIMENTAL
Intervention: Menopause Symptoms Treatment Satisfaction Questionnaire (MS-TSQ)
Number of subjects: 543
Study 15557412 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins and minerals supplementation (120 mg of ascorbic acid, 30 mg of vitamin E, 6 mg of beta carotene, 100 µg of selenium, and 20 mg of zinc)
Number of subjects: 13017
Study 15557412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13017
Study 15557412 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins and minerals supplementation
Number of subjects: 13017
Study 15557412 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins and minerals supplementation (men)
Number of subjects: 13017
Study 15557412 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins and minerals supplementation (women)
Number of subjects: 13017
Study 12212667 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult grip task with right hand
Number of subjects: 0
Study 12212667 — intervention group
Group type: COMPARATOR
Intervention: Easy grip task with right hand
Number of subjects: 0
Study 12212667 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult grip task with left hand
Number of subjects: 0
Study 12212667 — intervention group
Group type: COMPARATOR
Intervention: Easy grip task with left hand
Number of subjects: 0
Study 9836544 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant autolymphocyte therapy (ALT) after radical nephrectomy
Number of subjects: 45
Study 9836544 — intervention group
Group type: COMPARATOR
Intervention: Observation group (control)
Number of subjects: 45
Study 9836544 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal CT and chest radiograph
Number of subjects: 45
Study 9836544 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal CT alone
Number of subjects: 45
Study 9836544 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up schedule
Number of subjects: 45
Study 7858555 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril (mean dose 19mg/day)
Number of subjects: 20
Study 7858555 — intervention group
Group type: COMPARATOR
Intervention: doxazosin (mean dose 5.2mg/day)
Number of subjects: 20
Study 7858555 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril added to doxazosin
Number of subjects: 20
Study 7858555 — intervention group
Group type: COMPARATOR
Intervention: doxazosin added to enalapril
Number of subjects: 20
Study 2551121 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D2 4000 IU daily for 24 weeks
Number of subjects: 19
Study 2551121 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 4000 IU daily for 24 weeks
Number of subjects: 19
Study 776328 — intervention group
Group type: EXPERIMENTAL
Intervention: Talampicillin
Number of subjects: 47
Study 776328 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 47
Study 7198366 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 0.22 mg mounted on ophthalmic rods
Number of subjects: 11
Study 7198366 — intervention group
Group type: COMPARATOR
Intervention: Timolol eye drops (0.5%)
Number of subjects: 11
Study 31998164 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 18
Study 31998164 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 18
Study 29557078 — intervention group
Group type: EXPERIMENTAL
Intervention: Mazindol 1-3 mg/day
Number of subjects: 85
Study 29557078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 27668887 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination against HBV
Number of subjects: 0
Study 27668887 — intervention group
Group type: EXPERIMENTAL
Intervention: New strategies for predicting seroconversion
Number of subjects: 0
Study 27668887 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup studies in HIV patients with poor immunovirological status
Number of subjects: 0
Study 23772822 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive Early Childhood Curriculum (RECC)
Number of subjects: 65
Study 23772822 — intervention group
Group type: EXPERIMENTAL
Intervention: RECC plus explicit social-emotional classroom activities (RECC+)
Number of subjects: 65
Study 23772822 — intervention group
Group type: COMPARATOR
Intervention: Business-as-usual control
Number of subjects: 65
Study 22401315 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 38
Study 22401315 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 38
Study 21143436 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted referrals to existing community services and health promotion recommendations based on falls risk factors.
Number of subjects: 712
Study 21143436 — intervention group
Group type: COMPARATOR
Intervention: Standard care group (control).
Number of subjects: 712
Study 17369517 — intervention group
Group type: EXPERIMENTAL
Intervention: 15.2-meter walk
Number of subjects: 70
Study 17369517 — intervention group
Group type: COMPARATOR
Intervention: 6-minute walk
Number of subjects: 70
Study 17369517 — intervention group
Group type: EXPERIMENTAL
Intervention: 15.2-meter walk (highest quartiles >1.0 m/s)
Number of subjects: 70
Study 17369517 — intervention group
Group type: COMPARATOR
Intervention: 6-minute walk (highest quartiles >1.0 m/s)
Number of subjects: 70
Study 15098334 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex rehabilitation (28 therapeutic sessions over 1 month)
Number of subjects: 61
Study 15098334 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising group (control)
Number of subjects: 61
Study 10699107 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg birth weight at 12-18 hours of age and a second dose 12 hours later)
Number of subjects: 384
Study 10699107 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 384
Study 10699107 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 384
Study 9113583 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-second washout of sodium hyaluronate
Number of subjects: 107
Study 9113583 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-second washout of sodium hyaluronate
Number of subjects: 107
Study 9113583 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-second washout of sodium hyaluronate
Number of subjects: 107
Study 9113583 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual sodium hyaluronate concentration
Number of subjects: 107
Study 9113583 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinematic viscosity of sodium hyaluronate
Number of subjects: 107
Study 8222190 — intervention group
Group type: EXPERIMENTAL
Intervention: FUT‐175 (40 mg/h during cardiopulmonary bypass)
Number of subjects: 40
Study 8222190 — intervention group
Group type: COMPARATOR
Intervention: Control group (only heparin)
Number of subjects: 40
Study 2868753 — intervention group
Group type: EXPERIMENTAL
Intervention: Metipranolol 0.3%
Number of subjects: 10
Study 2868753 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.25%
Number of subjects: 10
Study 27987441 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported data
Number of subjects: 468
Study 27987441 — intervention group
Group type: COMPARATOR
Intervention: Administrative data
Number of subjects: 468